Form 4 for PASG Passage BIO, Inc.
Accepted 2024-01-03 00:00:00 ET · period of report 2023-12-31 · accession 0001209191-24-000369 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-03 | 2023-12-31 | PASG | Forman Mark S | Chief Medical Off | M - OptEx | — | +50.0K | 61.1K | +451% | — |
| D | 2024-01-03 | 2024-01-02 | PASG | Forman Mark S | Chief Medical Off | S - Sale+OE | $0.91 | -15.8K | 45.3K | -26% | -$14.4K |
| D | 2024-01-03 | 2023-12-31 | PASG | Forman Mark S | Chief Medical Off | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-31 | M | A | 50,000 | — | 61,082 | D | — | — | (F1) Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. (F2) Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-01-02 | S | D | 15,813 | $0.91 | 45,269 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2023-12-31 | M | D | 50,000 | $0.00 | 0 | D | — · — to — | 50,000 Common Stock | (F4) Each RSU represents a contingent right to receive one share of Issuer's common stock. (F5) 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |